Landlords becoming healthcare providers

In the super competitive real estate industry, one real estate investment firm has added virtual healthcare to its property’s amenities. Communidad Partners, which purchases, upgrades and manages real estate properties, is working with a nonprofit Veritas Impact Partners to provide a virtual healthcare program to residents, according to Fast Company, which spotlighted the feat.

The telehealth contract is with an unnamed Fortune 500 company that provides services to Communidad’s residents, with a special consideration for multifamily communities. Residents in the program can connect with nurses or doctors virtually through an app, where they can be diagnosed and treated with prescriptions. And Communidad is offering the program free to its residents.

The innovative program brings together housing and health care, bucking the typical way people in the U.S. obtain healthcare coverage. Typically, employment is tied to health care, meaning people who are unemployed or underemployed are usually at a higher risk of being uninsured or underinsured. 

So far, Communidad has implemented the program across 2,000 households. The spotlight on the program comes as more than six million people lost health insurance coverage due to the Covid-19 pandemic.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.